Live feed
·
PRReleasevia Quantisnow
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

ByQuantisnow·Wall Street's wire, on your screen.
LBRX· LB Pharmaceuticals Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LBRX (LB Pharmaceuticals Inc) and more on Quantisnow.